Please assess the completion status of the following clinical trial:

Trial Title: The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* sedation patients with dexmedetomidine or midazolam~* over 18 years old~Exclusion Criteria:~* Neurologic disease (stroke, seizure, dementia, hypoxic brain damage)~* Brain infection~* Alcoholics~* Major Depression Disorder, Schizophrenia, Anxiety disorder~* Hearing loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: None): Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr.
- Midazolam group (Type: None): Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).